Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-18T14:04:02.638Z Has data issue: false hasContentIssue false

8 - Chemotherapy and Radiotherapy in Esophageal Cancer

Published online by Cambridge University Press:  08 August 2009

By
Peter Harper  and
David Landau
Edited by
Sheila C. Rankin
Peter Harper
Affiliation:
Consultant, Medical Oncologist, Guy's and St. Thomas' Foundation Trust, London, UK
David Landau
Affiliation:
Consultant, Clinical Oncologist, Guy's and St. Thomas' Foundation Trust, London, UK
Sheila C. Rankin
Affiliation:
Guy's and St Thomas' Hospital
Get access

Summary

Introduction

Over 7600 cases of esophageal cancer are diagnosed in the United Kingdom every year. The overall survival is about 8%, and whilst there has been some improvement over time, this has not been dramatic and appears to date back to the mid 1980s (Figure 8.1). To improve these figures significantly will require prevention, earlier diagnosis, and more effective systemic therapies.

Development of chemotherapy

A UK multicenter trial, published in 1997, established epirubicin, cisplatin, and infusional 5-fluorouracil (5-FU; ECF) as the combination of choice in the UK and Europe. In this study 256 patients were randomly assigned to the then standard FAMTX regime (5-fluorouracil, doxorubicin, and methotrexate) or to ECF. About 51 patients had esophageal, 60 esophagogastric, and 145 gastric cancer. The overall response rate was 45% with ECF and 21% with FAMTX (p = 0.0002), the median survival was 8.9 versus 5.7 months with FAMTX and, at 1 year, 36 versus 21% of the patients were alive.

With improvements in chemotherapy supportive medication, for example, the introduction of HT-3 antagonists for anti-emetic cover, cisplatin-based chemotherapy has become the treatment of choice for the majority of patients requiring chemotherapy.

Recent developments in drug therapy have increased the options for trials of systemic therapy. None has yet been proven to improve on ECF in terms of efficacy, although recent trials have shown at least equivalent activity with reduced toxicity with some new agents.

Type
Chapter
Information
Carcinoma of the Esophagus , pp. 122 - 133
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cancer Research UK (CRUK). Oesophageal Cancer survival statistics. http://info.cancerresearchuk.org/cancerstats/types/oesophagus/survival/ (2004).
Webb, A., Cunningham, D., Scarffe, J. H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15 (1997), 261–7.CrossRefGoogle ScholarPubMed
Herskovic, A., Martz, K., al-Sarraf, M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 326 (1992), 1593–8.CrossRefGoogle ScholarPubMed
Cooper, J. S., Guo, M. D., Herskovic, A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA, 281 (1999), 1623–7.CrossRefGoogle ScholarPubMed
Urschel, J. D., Vasan, H., and Blewett, C. J.. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg, 183 (2002), 274–9.CrossRefGoogle ScholarPubMed
Kelsen, D. P., Ginsberg, R., Parak, T. F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 339 (1998), 1979–84.CrossRefGoogle ScholarPubMed
Medical Research Council (MRC). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359:9319 (2002), 1727–33.CrossRef
Kaklamanos, I. G., Walker, G. R., Ferry, K., et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol, 10 (2003), 754–61.CrossRefGoogle ScholarPubMed
Forshaw, M. J., Gossage, J. A., and Mason, R. C.. Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. Surgeon, 3 (2005), 373–82, 422.CrossRefGoogle ScholarPubMed
Munden, R. F., Macapinlac, H. A., Erasmus, J. J., et al. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging, 21 (2006), 137–45.CrossRefGoogle ScholarPubMed
Olaussen, K. A., Dunant, A., Fouret, P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355 (2006), 983–91.CrossRefGoogle ScholarPubMed
Urschel, J. D. and Vasan, H.. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg, 185 (2003), 538–43.CrossRefGoogle ScholarPubMed
Minsky, B. D., Pajak, T. F., Ginsberg, R. J., et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol, 20 (2002), 1167–74.CrossRefGoogle ScholarPubMed
Cominos, M., Mosleh-Shirazi, M. A., Tait, D., et al. Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. Br J Radiol, 78 (2005), 1069–74.CrossRefGoogle ScholarPubMed
Gaya, A. M. and Ashford, R. F.. Cardiac complications of radiation therapy. Clin Oncol, 17 (2005), 153–9.CrossRefGoogle ScholarPubMed
Moureau-Zabotto, L., Touboul, E., Lerouge, D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys, 63 (2005), 340–5.CrossRefGoogle ScholarPubMed
Leong, T., Everitt, C., Yuen, K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol, 78 (2006), 254–61.CrossRefGoogle ScholarPubMed
Nutting, C. M., Bedford, J. L., Cosgrove, V. P., et al. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol, 61 (2001), 157–63.CrossRefGoogle ScholarPubMed
Chandra, A., Guerrero, T. M., Lui, H. H., et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol, 77 (2005), 247–53.CrossRefGoogle ScholarPubMed
Armanios, M., Xu, R., Forastiere, A. A., et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol, 22 (2004), 4495–9.CrossRefGoogle ScholarPubMed
Dexter, S. P., Sue-Ling, H., McMahon, M. J., et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut, 48 (2001), 667–70.CrossRefGoogle ScholarPubMed
Bedard, E. L., Inculet, R. I., Malthaner, R. A., et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer, 91 (2001), 2423–30.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Rice, T. W., Adelstein, D. J., Chidel, M. A., et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg, 126 (2003), 1590–6.CrossRefGoogle ScholarPubMed
Tachibana, M., Yoshimura, H., Kinugasa, S., et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol, 29 (2003), 580–7.CrossRefGoogle ScholarPubMed
Sumpter, K., Harper-Wynne, C., Cunningham, D., et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer, 92 (2005), 1976–83.CrossRefGoogle Scholar
Cunningham, D., Rao, S., Starling, N., et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol, 24 (2006), LBA4017.Google Scholar
Al-Batran, S., Hartmann, J., Probst, S., et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J Clin Oncol, 24 (2006), LBA4016.Google Scholar
Kang, Y., Kang, W. K., Shin, D. B., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol, 24 (2006), LBA4017.Google Scholar
Bleiberg, H., Conroy, T., Paillot, B., et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer, 33 (1997), 1216–20.CrossRefGoogle ScholarPubMed
Ajani, J. A., Fodor, M. B., Tjulandin, S. A., et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23 (2005), 5660–7.CrossRefGoogle ScholarPubMed
Burge, M. E., Smith, D., Topham, C., et al. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer, 94 (2006), 1281–6.CrossRefGoogle ScholarPubMed
Shah, M. A., Ramanathan, R. K., Ilson, D. H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol, 24 (2006), 5201–6.CrossRefGoogle ScholarPubMed
Lorenzen, S., Duyster, J., Lersch, C., et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer, 92 (2005), 2129–33.CrossRefGoogle ScholarPubMed
Assersohn, L., Brown, G., Cunningham, D., et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol, 15 (2004), 64–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×